Please ensure Javascript is enabled for purposes of website accessibility

Powerful Cholesterol-Lowering Drugs on Their Way

By Brian Orelli, PhD - Apr 16, 2013 at 6:46PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

However, these newcomers won't replace statins.

There are plenty of Food and Drug Administration approved cholesterol-lowering drugs available for patients. And they're quite powerful. Statins, such as Pfizer's (PFE -1.17%) Lipitor or AstraZeneca's Crestor, can lower bad LDL cholesterol by as much as 60% and increase good HDL by up to 15%.

For some patients, that's not enough, though. Taking statins alone fails to lower LDL cholesterol to healthy levels in as much as 50% of patients. Another 3%-4% of patients can't take statins because of side effects.

One option is for patients to take Merck's (MRK -0.76%) Zetia or Vytorin, which is a combination of Zetia and a statin called Zocor. Adding Zetia to a statin can lower LDL cholesterol by 25%. While it's clear that the cholesterol goes down on the laboratory test, it isn't as clear that the lower cholesterol translates into better outcomes.

A trial a few years ago failed to show that Vytorin could reduce plaque in arteries compared to a statin along. But those tests aren't perfect. The definitive answer will come from an outcomes trial, expected to read out next year.

New targets
Statins work by inhibiting HMG-CoA reductase, an enzyme in the pathway that converts a molecule called HMG-CoA into cholesterol. Zetia works by inhibiting cholesterol absorption in the intestine.

Drugmakers are working on a couple of other new targets to help lower cholesterol.

Aegerion Pharmaceutical's Juxtapid inhibits microsomal triglyceride transfer protein, which helps assemble very low-density lipoprotein, which are eventually made into LDL cholesterol in the blood stream.

Isis Pharmaceuticals (IONS 0.48%) and Sanofi's Kynamro inhibits the production of apolipoprotein B, a precursor of LDL cholesterol.

Both Juxtapid and Kynamro are approved to treat a genetic disorder called homozygous familial hypercholesterolemia, which causes extremely high cholesterol levels. While both drugs are quite effective, they both have side effects that will probably keep them from being used in patients with cholesterol levels that that are marginally high.

Proprotein convertase subtilisin/kexin type 9, or PCSK9 -- the newest target drugmakers are pursuing -- looks like it's going to be a good one based on the number of different companies going after it. PCSK9 promotes the degradation of a receptor responsible for metabolizing LDL cholesterol.

Sanofi and Regeneron Pharmaceuticals (REGN -0.05%) are working on a drug codenamed REGN727/SAR236553 that inhibits PCSK9. In a phase 2 trial, the drug reduced LDL cholesterol by 28.9% to 67.9% compared with a 10.7% reduction in patients receiving placebo. Amgen (AMGN -0.53%) also has a PCSK9 inhibitor called AMG 145, which reduced LDL cholesterol by up to 66% in patients already taking a statin.

Alnylam Pharmaceuticals recently partnered with The Medicines Company to develop its PCSK9 drug. Rather than inhibiting the protein directly, Alnylam uses an RNAi strategy to lower the production of the protein.

In Pfizer's trial of RN-316, patients taking statins saw their cholesterol fall by 80% after the first treatment. Some patients saw their levels fall so low, they didn't qualify for a second injection.

Roche also has PCSK9 drugs in development. The Swiss pharma has kept its data close to its chest, reportedly because of all the competition.

Added benefit
Statins aren't going anywhere given their effectiveness and tolerability. AstraZeneca has to worry more about competition from generic Lipitor than it does PCSK9 inhibitors.

But there's still a nice large market of people that could take a statin and a PCSK9 inhibitor. Investors should keep an eye on the space, but it'll be difficult to pick a winner until we see data from large phase 3 trials next year.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.81 (-1.17%) $0.59
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$91.40 (-0.76%) $0.70
Amgen Inc. Stock Quote
Amgen Inc.
AMGN
$242.68 (-0.53%) $-1.28
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$658.89 (-0.05%) $0.31
Ionis Pharmaceuticals, Inc. Stock Quote
Ionis Pharmaceuticals, Inc.
IONS
$38.58 (0.48%) $0.18
Sanofi Stock Quote
Sanofi
SNY
$53.18 (1.51%) $0.79
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$64.29 (1.53%) $0.97
Alnylam Pharmaceuticals, Inc. Stock Quote
Alnylam Pharmaceuticals, Inc.
ALNY
$129.27 (0.75%) $0.96
The Medicines Company Stock Quote
The Medicines Company
MDCO

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
328%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.